Antibiotic resistance is a phenomenon that knows no geographical borders, so addressing this crisis is a worldwide public health priority. While total global resistance rates are difficult to estimate and vary between countries, an international report asserts that the development of new antibacterials is essential to ensuring the future ability to treat bacterial infections 1 . Bacteriophage (phage) therapy is a likely contributor to resolving potentially devastating effects of antibiotic resistance, yet no phage product currently holds a marketing authorisation that would permit their free use in clinical medicine outside of former countries of the Soviet Union, where phage therapy is a long-standing practice 2, 3 . In the interim, the compassionate use of phage therapy (cPT) remains a possible treatment avenue for cases of antibiotic failure, and several competency centres, physicians, and researchers have achieved therapeutic benefits with this option. As antibiotic resistance continues to rise, there is much to be done in order to streamline cPT efforts, particularly in terms of phage sourcing, in order to reach more patients in an efficient, effective, and safe manner. This article highlights how cPT can be coordinated, and describes the experience of cPT in Australia.
Compassionate treatment denotes the use of unapproved medi- . In Australia, access to unapproved therapeutic goods can be attained through a Special Access Scheme (SAS), which is divided into three categories (A: notification for the seriously ill; B: application; C: notification of use of specified products) 8 . The Second Australian report on Antimicrobial Use and Resistance in Human Health has identified 14 target pathogens for which resistance rates to certain antibiotics varied widely from <1 to 96% of isolates, indicating an existing need for alternative treatment options, such as cPT 9 .
The use of phage for compassionate treatment of antibiotic-resistant infections is increasing, with >20 published papers from experimental treatment centres, pilot studies, and case reports since 2000, reviewed in [10] [11] [12] [13] [14] [15] . A diversity of infections have been treated by cPT, including endocarditis 16 , diabetic toe ulcers 14, 17 , abdominal cysts 18 , prostatitis 15, 19, 20 , otitis 15 and osteomyelitis 12 , encompassing both local and systemic routes of administration.
One case report described the treatment of a refractory urinary tract infection caused by a multidrug-resistant strain of Pseudomonas 
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